Search results for " cerebral."

showing 10 items of 271 documents

Hemispheric differences in specificity effects in talker identification

2010

In the visual domain, Marsolek and colleagues (1999, 2008) have found support for two dissociable and parallel neural subsystems underlying object and shape recognition: an abstract-category subsystem that operates more effectively in the left cerebral hemisphere (LH), and a specific-exemplar subsystem that operates more effectively in the right cerebral hemisphere (RH). Evidence of this asymmetry has been observed in priming specificity for linguistic (words, pseudoword forms) and nonlinguistic (objects) stimuli. In the auditory domain, the authors previously found hemispheric asymmetries in priming effects for linguistic (spoken words) and nonlinguistic (environmental sounds) stimuli. In …

Linguistics and Languagemedicine.medical_specialtyProperty (programming)Cervell--Localització de funcionsmedia_common.quotation_subjectObject (grammar)Experimental and Cognitive PsychologyAudiologyLanguage and LinguisticsPerceptionmedicineHumansDominance Cerebralmedia_commonCommunicationbusiness.industryHemisphere asymmetriesReconeixement de la parlaTalker identificationSensory SystemsSemanticsPseudowordAcoustic StimulationPattern Recognition VisualPrimingLateralitySpeech PerceptionTest phaseIdentification (psychology)Specificity effectsCuesPsychologybusinessPriming (psychology)Attention, Perception, & Psychophysics
researchProduct

Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre…

2020

Background and aims: HCV is associated with an increased risk of cardiovascular events (CV). Whether HCV clearance by direct-acting antivirals (DAA) reduces incident CV disease is poorly understood. We investigate whether HCV eradication reduces CV events. Methods: In a prospective multicentre study, 2204 HCV patients (F0–F2:29.5%, F3–F4: 70.5%) were enrolled. Males were 48%, median age was 68 (59–74) years and BMI 25.9 (23.1–28); 24.7% were smokers, 18% had diabetes, 13.2% had cholesterol levels >200 mg/dl and 9.1% took statins, 44% had hypertension. During an overall median follow-up of 28 (24–39) months, incident CV events, such as ischemic heart disease (IHD) and ischemic cerebral st…

Liver CirrhosisMale0301 basic medicineCirrhosisMyocardial IschemiaComorbidityHepacivirusDisease030204 cardiovascular system & hematologyChronic hepatitis Cmedicine.disease_causechemistry.chemical_compound0302 clinical medicineRisk FactorsProspective StudiesIschemic heart disease Ischemic cerebral stroke Chronic hepatitis C CirrhosisIncidenceIncidence (epidemiology)SmokingMiddle AgedViral LoadStrokeItalyHypertensionFemaleCardiology and Cardiovascular MedicineDirect actingmedicine.medical_specialtyIschemic heart diseaseHepatitis C virusHypercholesterolemiaAntiviral Agents03 medical and health sciencesDiabetes mellitusInternal medicineDiabetes MellitusmedicineHumansViremiaAgedCirrhosibusiness.industryCholesterolHepatitis C Chronicmedicine.disease030104 developmental biologychemistryRelative riskIschemic cerebral strokeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessAtherosclerosis
researchProduct

Endogenous THBD (Thrombomodulin) Mediates Angiogenesis in the Ischemic Brain—Brief Report

2020

Objective: THBD (thrombomodulin) is part of the anticoagulant protein C-system that acts at the endothelium and is involved in anti-inflammatory and barrier-stabilizing processes. A recombinant soluble form of THBD was shown to have protective effects in different organs, but how the endogenous THBD is regulated during ischemia, particularly in the brain is not known to date. The aim of this study was to investigate the role of THBD, especially in brain endothelial cells, during ischemic stroke. Approach and Results: To induce ischemic brain damage, we occluded the middle cerebral artery of mice. We found an increased endothelial expression of Thbd in the peri-infarct area, whereas in the …

Male0301 basic medicineEndotheliumAngiogenesismedicine.drug_classThrombomodulinNeovascularization PhysiologicInflammationEndogeny030204 cardiovascular system & hematologyThrombomodulinlaw.invention03 medical and health sciences0302 clinical medicinelawAnimalsMedicineStrokeCells CulturedMice Knockoutbusiness.industryAnticoagulantBrainEndothelial CellsInfarction Middle Cerebral Arterymedicine.disease3. Good healthMice Inbred C57BLDisease Models Animal030104 developmental biologymedicine.anatomical_structureRecombinant DNACancer researchmedicine.symptomCardiology and Cardiovascular MedicinebusinessSignal TransductionArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants

2020

Mice lacking GAD1 show neonatal mortality, but the human phenotype associated with GAD1 disruption is poorly characterized. Neuray et al. describe six patients with biallelic GAD1 mutations, presenting with early-infantile onset epilepsy, neurodevelopmental delay, muscle weakness and non-CNS manifestations.

Male0301 basic medicineGlutamate decarboxylaseMalalties cerebralsNeurotransmissorsNeurodevelopmental delayEpilepsy0302 clinical medicineMESH: ChildAge of OnsetChildcleft palateGAD1AcademicSubjects/SCI01870Glutamate DecarboxylaseGlutamate receptorMuscle weakness//purl.org/becyt/ford/3.1 [https]NeurotransmittersMESH: InfantHypotoniamuscle weakneCleft palateMESH: EpilepsyChild PreschoolMuscle Hypotonia[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]//purl.org/becyt/ford/3 [https]FemaleBrain diseasesAbnormalitiesmedicine.symptomMultiplemedicine.drugcleft palate; epilepsy; GAD1; muscle weakness; neurodevelopmental delayMESH: Glutamate Decarboxylasemedicine.medical_specialtyMESH: Abnormalities MultipleMESH: MutationMESH: Age of OnsetBiologyInhibitory postsynaptic potentialGAD1 cleft palate epilepsy muscle weakness neurodevelopmental delay.gamma-Aminobutyric acidGAD1neurodevelopmental delay03 medical and health sciencesExcitatory synapseInternal medicinemedicineHumansAbnormalities MultiplePreschoolAllelesMESH: Neurodevelopmental Disordersmuscle weaknessMESH: HumansEpilepsyMESH: Muscle HypotoniaMESH: AllelesMESH: Child PreschoolInfantmedicine.diseaseMESH: MaleEpilèpsiaEditor's Choice030104 developmental biologyEndocrinologyNeurodevelopmental DisordersMutationepilepsyAcademicSubjects/MED00310Neurology (clinical)Cleft palate; Epilepsy; GAD1; Muscle weakness; Neurodevelopmental delay; Abnormalities Multiple; Age of Onset; Alleles; Child; Child Preschool; Epilepsy; Female; Glutamate Decarboxylase; Humans; Infant; Male; Muscle Hypotonia; Mutation; Neurodevelopmental DisordersMESH: Female[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology030217 neurology & neurosurgeryReports
researchProduct

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention

2021

Background and Purpose: Clinical trials on stroke prevention in patients with atrial fibrillation have consistently shown clinical benefit from either warfarin or non–vitamin K antagonist oral anticoagulants (NOACs). NOAC-treated patients have consistently reported to be at lower risk for intracerebral hemorrhage (ICH) than warfarin-treated patients. The aims of this prospective, multicenter, multinational, unmatched, case-control study were (1) to investigate for risk factors that could predict ICH occurring in patients with atrial fibrillation during NOAC treatment and (2) to evaluate the role of CHA 2 DS 2 -VASc and HAS-BLED scores in the same setting. Methods: Cases were consecutive pa…

MaleAdministration Oral030204 cardiovascular system & hematologySettore MED/110302 clinical medicine80 and overrisk factorsMedicineatrial fibrillationProspective StudiesAged 80 and overatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matter; Administration Oral; Aged; Aged 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; StrokeAtrial fibrillationMiddle AgedVitamin K antagonist3. Good healthStrokeAdministrationSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinewhite mattermedicine.drugOralmedicine.medical_specialtymedicine.drug_classSettore MED/26Lower riskAntithrombins03 medical and health sciencesInternal medicineHumanscardiovascular diseaseslogistic modelAgedAdvanced and Specialized NursingIntracerebral hemorrhagecerebral hemorrhagebusiness.industryWarfarinmedicine.diseaseClinical trialatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matterCase-Control StudiesConcomitantHeart failureNeurology (clinical)businesslogistic models030217 neurology & neurosurgeryStroke
researchProduct

Therapeutic Application of 20-kHz Transcranial Ultrasound in an Embolic Middle Cerebral Artery Occlusion Model in Rats

2007

Background and Purpose— Therapeutic application of diagnostic ultrasound has been shown to improve recanalization rates in patients with acute cerebral vessel occlusion. There is experimental evidence that low-frequency ultrasound may be superior. This study was designed to evaluate the therapeutic efficacy and safety of low-frequency ultrasound in an embolic middle cerebral artery occlusion model in rats. A parameter setting was used that had not previously shown any side effects and interactions with healthy rat brain tissue. Methods— Male Wistar rats were submitted to middle cerebral artery clot embolism and transcranial treatment with 20-kHz continuous-wave ultrasound (0.2 W/cm 2 ), ei…

MaleAdvanced and Specialized Nursingbusiness.industryUltrasonic Therapymedicine.medical_treatmentUltrasoundInfarction Middle Cerebral ArteryThrombolysismedicine.diseaseRatsTranscranial DopplerDisease Models AnimalEmbolismmedicine.arteryAnesthesiaMiddle cerebral arteryOcclusionmedicineAnimalsNeurology (clinical)Rats WistarCardiology and Cardiovascular MedicinebusinessPlasminogen activatorStrokeStroke
researchProduct

Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice.

2012

Stroke represents an attractive target for stem cell therapy. Although different types of cells have been employed in animal models, a direct comparison between cell sources has not been performed. The aim of our study was to assess the effect of human multipotent adult progenitor cells (hMAPCs) and human mesenchymal stem cells (hMSCs) on endogenous neurogenesis, angiogenesis and inflammation following stroke. BALB/Ca-RAG 2(-/-) γC(-/-) mice subjected to FeCl(3) thrombosis mediated stroke were intracranially injected with 2 × 10(5) hMAPCs or hMSCs 2 days after stroke and followed for up to 28 days. We could not detect long-term engraftment of either cell population. However, in comparison w…

MaleAnatomy and PhysiologyMousemedicine.medical_treatmentCell therapyMiceCell MovementMolecular Cell BiologyNeurobiology of Disease and RegenerationMedicineMultidisciplinaryNeuronal MorphologyNeurogenesisQRBrainInfarction Middle Cerebral ArteryAnimal ModelsStem-cell therapyStrokeAdult Stem Cellsmedicine.anatomical_structureNeurologyMedicineResearch ArticleAdult stem cellCell PhysiologyHistologyCell SurvivalCerebrovascular DiseasesScienceTherapeutic effectsNeurophysiologyNeovascularization PhysiologicSubventricular zoneMesenchymal Stem Cell TransplantationNeurological SystemModel OrganismsAnimalsHumansProgenitor cellBiologyTransplantationbusiness.industryMultipotent Stem CellsMesenchymal stem cellMultipotent Stem CellCellular NeuroscienceImmunologyCancer researchMolecular NeurosciencebusinesshMAPC and hMSCNeurosciencePLoS ONE
researchProduct

Recollection and familiarity in dense hippocampal amnesia: A case study

2004

In the amnesia literature, disagreement exists over whether anterograde amnesia involves recollective-based recognition processes and/or familiarity-based ones depending on whether the anatomical damage is restricted to the hippocampus or also involves adjacent areas, particularly the entorhinal and perirhinal cortices. So far, few patients with well documented anatomical lesions and detailed assessment of recollective and recognition performance have been described. We report a comprehensive neuroanatomical assessment and detailed investigation of the anterograde memory functions of a previously described severe amnesic patient (VC). The results of four previously published neuroradiologic…

MaleAnterograde amnesiaMagnetic Resonance SpectroscopyhippocampusrecollectionCognitive NeuroscienceAmnesiaExperimental and Cognitive PsychologyNeuropsychological Testsrecognition memoryBehavioral NeuroscienceHippocampuamnesiaReference ValuesPerirhinal cortexmedicineImage Processing Computer-AssistedSemantic memoryHumansMemory disorderDominance Cerebralhippocampus; perirhinal cortex; recognition memory; amnesia; recollection; familiarityRecognition memoryAgedBrain MappingfamiliaritySettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaRecallRetrograde amnesiaRetention Psychologyperirhinal cortexmedicine.diseaseAmnesia AnterogradeAmygdalaMagnetic Resonance ImagingTemporal Lobemedicine.anatomical_structureMental RecallParahippocampal Gyrusmedicine.symptomPsychologyNeuroscience
researchProduct

Apoe genotypes and brain imaging classes in normal cognition, mild cognitive impairment, and alzheimer’s disease: A longitudinal study

2020

Objective: To evaluate in 419 stroke-free cognitively normal subjects (CN) aged 45-82 years covering during a long prospective study (11.54 ± 1.47 years) the preclinical to dementia spectrum: 1) the distribution of small vessel disease (V) and brain atrophy (A) aggregated as following: V−/A−, V−/A+, V+/A−, V+/A+; 2) the relationship of these imaging classes with individual apolipoprotein E (APOE) genotypes; 3) the risk of progression to Alzheimer Disease (AD) of the individual APOE genotypes. Methods: Participants underwent one baseline (t0), and 4 clinical and neuropsychological assessments (t1,t2,t3, and t4). Brain MRI was performed in all subjects at t0, t2, t3 and t4.. White matter hyp…

MaleApolipoprotein Emedicine.medical_specialtyGenotypeApolipoprotein E4NeuroimagingNeuropsychological TestsAPOE genotypes Brain imaging classes Caudate atrophy Global cerebral atrophy Lacunes White matter hyperintensities Aged Aged 80 and over Alzheimer Disease Apolipoprotein E4 Apolipoproteins E Brain Case-Control Studies Cognitive Dysfunction Disease Progression Female Genotype Humans Longitudinal Studies Magnetic Resonance Imaging Male Middle Aged Neuroimaging Neuropsychological Tests Risk Factorsbrain imaging classesApolipoproteins EAtrophyNeuroimagingAlzheimer DiseaseRisk FactorsInternal medicineGlobal brain atrophymedicineHumansDementiaCognitive DysfunctionLongitudinal Studiescaudate atrophyAgedglobal cerebral atrophyAged 80 and overAPOE genotypesbusiness.industryNeuropsychologyBrainMiddle Agedwhite matter hyperintensitiesmedicine.diseaseMagnetic Resonance ImagingHyperintensityNeurologyCase-Control StudiesDisease ProgressionCardiologyFemaleNeurology (clinical)Alzheimer's diseasebusiness
researchProduct

Inhibition of iNOS activity by 1400W decreases glutamate release and ameliorates stroke outcome after experimental ischemia

2005

Background and purpose. It has been shown that the reversed operation of glutamate transporters when ATP levels fall accounts for most glutamate release induced by severe cerebral ischemia. Nitric oxide (NO) is formed after ischemia and causes ATP depletion. Our purpose is to test if NO release from inducible NO synthase (iNOS) after stroke may cause a delayed glutamate release due to ATP depletion that might underlie progression of the ischemic infarct. We have studied the effect of the highly selective inhibitor of iNOS activity 1400W on brain ATP levels, extracellular glutamate, and stroke outcome after transient focal cerebral ischemia in rats. Methods. To induce focal ischemia, the mid…

MaleBenzylaminesAmino Acid Transport System X-AGIschemiaAmidinesInfarctionDown-RegulationGlutamic AcidNitric Oxide Synthase Type IIL-argininePharmacologyNeuroprotectionNitric oxidelcsh:RC321-571chemistry.chemical_compoundAdenosine TriphosphateWestern blotmedicine.arteryStroke outcomeMedicineAnimalscardiovascular diseasesEnzyme InhibitorsRats Wistarlcsh:Neurosciences. Biological psychiatry. Neuropsychiatrymedicine.diagnostic_testbusiness.industryGlutamate receptorBrainInfarction Middle Cerebral ArteryNitric oxideCerebral Infarctionmedicine.diseaseNeuroprotectionRatsATPStrokeDisease Models AnimalNeuroprotective AgentsTreatment OutcomeNeurologychemistryCytoprotectionIschemic Attack TransientAnesthesiaMiddle cerebral arteryNitric Oxide SynthaseGlutamatebusinessNeurobiology of Disease
researchProduct